Floatz logo

ALLOPREGNAN-3.ALPHA.-OL-20-ONE

Postpartum Depression

Supernus Pharmaceuticals, Inc.Small moleculePhase 3Dormant
BBB
72/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
61/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Postpartum Depression cohort.

Asset / SponsorPhaseRating
Sertraline
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Phase 4BB
Zuranolone
Biogen
Phase 3BB
CYCLOHEXANEACETIC ACID, 1-(AMINOMETHYL)-
Stanford University
Phase 4BB
Lpcn 1154A
Lipocine Inc.
Phase 3BB
Cipralex
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Phase 3BB

View all 12 →

Same molecule, other indications

ALLOPREGNAN-3.ALPHA.-OL-20-ONE is also rated in:

Alzheimer diseaseDormant
B
Indicative ·
60 / 100
View asset →
post-traumatic epilepsyDormant
B
Indicative ·
57 / 100
View asset →
traumatic brain injuryDormant
CCC
Indicative ·
54 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →